Pulmonary hypertension pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{Pulmonary hypertension}}
{{Pulmonary hypertension}}
{{CMG}}
{{CMG}}   '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]],
 


==Overview==
==Overview==

Revision as of 16:27, 8 September 2011

Pulmonary Hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary hypertension from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pulmonary hypertension pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Pulmonary hypertension pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary hypertension pathophysiology

CDC on Pulmonary hypertension pathophysiology

Pulmonary hypertension pathophysiology in the news

Blogs on Pulmonary hypertension pathophysiology

Directions to Hospitals Treating Pulmonary hypertension

Risk calculators and risk factors for Pulmonary hypertension pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assistant Editor(s)-in-Chief: Ralph Matar,


Overview

There are different types and causes of pulmonary hypertension, however most of them share the same pathophysiology: An initiating factor leads to increased resistance in the pulmonary vasculature. As a consequence, the right ventricle adapts by increasing right ventricular systolic pressures to preserve the cardiac output from the right heart. With time, increasing right ventricular systolic pressures will subsequently result in chronic changes in the pulmonary circulation and progressive remodeling of the vessel walls further exacerbating the pulmonary hypertension.

The ability of the right ventricle to adapt to increased pulmonary vascular resistance is influenced by several factors, including the age of the patient at onset, rapidity of onset of pulmonary hypertension and coexisting hypoxemia.

All classes of pulmonary hypertension are associated with narrowing and obliteration of the pulmonary arterioles due to thickening of the intima by fibromuscular dysplasia.This constant finding has created increased our interest in the role of endothelial injury and the release of vasoactive mediators in the pathogenesis of pulmonary hypertension.These mediators include both vasoconstrictors and vasodilators.The main vasoconstrictor is Endothelin, whereas Nitric Oxide (NO), PGI2 and endothelium derived hyperpolarizing factor (EDHF) are vasodilators of which NO is the most potent in reversing the effects of Endothelin.[1]

  1. Higenbottam Tim(1994) "Pathophysiology of Pulmonary Hypertension, A role for endothelial dysfunction" Chest journal"